William Anderson

List of Publications by Year
in descending order

108 papers	4,061 citations	117625 34 h-index	138484 58 g-index
111 all docs	111 docs citations	111 times ranked	5688 citing authors

#	Article	IF	Citations
1	OSTEOGENESIS IMPERFECTA IS LINKED TO BOTH TYPE I COLLAGEN STRUCTURAL GENES. Lancet, The, 1986, 328, 69-72.	13.7	193
2	Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation. Molecular Therapy, 2018, 26, 354-365.	8.2	185
3	Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood, 2005, 105, 2510-2518.	1.4	165
4	Î³Î´ T cells for cancer immunotherapy. OncoImmunology, 2014, 3, e27572.	4.6	158
5	Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes and Cancer, 1999, 26, 275-285.	2.8	145
6	A molecular map of mesenchymal tumors. Genome Biology, 2005, 6, R76.	9.6	119
7	Human Î³Î´ T Lymphocytes Are Licensed for Professional Antigen Presentation by Interaction with Opsonized Target Cells. Journal of Immunology, 2012, 188, 1708-1716.	0.8	119
8	New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK. Clinical Cancer Research, 2013, 19, 5814-5821.	7.0	119
9	Antitumor activity without on-target off-tumor toxicity of GD2â€“chimeric antigen receptor T cells in patients with neuroblastoma. Science Translational Medicine, 2020, 12, .	12.4	108
10	Relationship Between MYCN Copy Number and Expression in Rhabdomyosarcomas and Correlation With Adverse Prognosis in the Alveolar Subtype. Journal of Clinical Oncology, 2005, 23, 880-888.	1.6	106
11	Embryonal precursors of Wilms tumor. Science, 2019, 366, 1247-1251.	12.6	101
12	Neuroblastoma Killing Properties of VÎ´2 and VÎ´2-Negative Î³Î´T Cells Following Expansion by Artificial Antigen-Presenting Cells. Clinical Cancer Research, 2014, 20, 5720-5732.	7.0	99
13	Clusterin, a Haploinsufficient Tumor Suppressor Gene in Neuroblastomas. Journal of the National Cancer Institute, 2009, 101, 663-677.	6.3	87
14	Disruption of Imprinted Genes at Chromosome Region 11p15.5 in Paediatric Rhabdomyosarcoma. Neoplasia, 1999, 1, 340-348.	5.3	85
15	Identification of new Wilms tumour predisposition genes: an exome sequencing study. The Lancet Child and Adolescent Health, 2019, 3, 322-331.	5.6	82
16	Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity. Cancer Research, 2015, 75, 3043-3053.	0.9	78
17	Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell. Science Advances, 2021, 7, .	10.3	78
18	A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. , 2000, 28, 220-226.		75

#	Article	IF	Citations
19	Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. Nature Communications, 2020, 11, 4324.	12.8	75
20	Polyphenol E Enhances the Antitumor Immune Response in Neuroblastoma by Inactivating Myeloid Suppressor Cells. Clinical Cancer Research, 2013, 19, 1116-1125.	7.0	74
21	Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. Nature Communications, 2018, 9, 2378.	12.8	72
22	Cytogenetic abnormalities in 42 rhabdomyosarcoma: A United Kingdom cancer cytogenetics group study. Medical and Pediatric Oncology, 2001, 36, 259-267.	1.0	70
23	Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor. Molecular Therapy, 2017, 25, 1234-1247.	8.2	69
24	PAX3-FKHR Induces Morphological Change and Enhances Cellular Proliferation and Invasion in Rhabdomyosarcoma. American Journal of Pathology, 2001, 159, 1089-1096.	3.8	67
25	Clinical and pathological features of paediatric malignant rhabdoid tumours. Pediatric Blood and Cancer, 2010, 54, 29-34.	1.5	65
26	Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. Clinical and Translational Oncology, 2012, 14, 271-279.	2.4	60
27	An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers. PLoS ONE, 2016, 11, e0152196.	2.5	57
28	Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy. Frontiers in Immunology, 2018, 9, 1409.	4.8	55
29	Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein. Journal of Experimental Medicine, 2005, 202, 1399-1410.	8.5	53
30	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. European Journal of Cancer, 2020, 127, 52-66.	2.8	52
31	Novel formation and amplification of thePAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. , 1996, 17, 7-13.		50
32	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. European Journal of Cancer, 2019, 121, 224-235.	2.8	44
33	Patterns of shift in ADC distributions in abdominal tumours during chemotherapyâ€"feasibility study. Pediatric Radiology, 2011, 41, 99-106.	2.0	43
34	In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis. Cancer Research, 2019, 79, 5382-5393.	0.9	42
35	Response Without Shrinkage in Bilateral Wilms Tumor: Significance of Rhabdomyomatous Histology. Journal of Pediatric Hematology/Oncology, 2002, 24, 31-34.	0.6	40
36	Pilot study of F18-Fluorodeoxyglucose Positron Emission Tomography/computerised tomography in Wilmsâ€™ tumour: Correlation with conventional imaging, pathology and immunohistochemistry. European Journal of Cancer, 2011, 47, 389-396.	2.8	40

#	Article	IF	Citations
37	The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. Growth Factors, 2006, 24, 197-208.	1.7	38
38	Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case. Cancer Genetics and Cytogenetics, 2003, 140, 73-77.	1.0	35
39	The Brn-3b Transcription Factor Regulates the Growth, Behavior, and Invasiveness of Human Neuroblastoma Cells in Vitro and in Vivo. Journal of Biological Chemistry, 2004, 279, 21617-21627.	3.4	35
40	Postâ€thaw viability of cryopreserved peripheral blood stem cells (<scp>PBSC</scp>) does not guarantee functional activity: important implications for quality assurance of stem cell transplant programmes. British Journal of Haematology, 2016, 174, 942-951.	2.5	35
41	Fluorescence imaging in pediatric surgery: State-of-the-art and future perspectives. Journal of Pediatric Surgery, 2021, 56, 655-662.	1.6	35
42	MYCN as a target for cancer immunotherapy. Cancer Immunology, Immunotherapy, 2008, 57, 693-700.	4.2	33
43	Engineering Î³Î´T cells limits tonic signaling associated with chimeric antigen receptors. Science Signaling, 2019, 12, .	3.6	29
44	Rhabdomyosarcoma Subtyping by Immunohistochemical Assessment of Myogenin: Tissue Array Study and Review of the Literature. Pathology and Oncology Research, 2008, 14, 233-238.	1.9	27
45	Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2â€²-Deoxycytidine. Cancer Immunology, Immunotherapy, 2011, 60, 1243-1255.	4.2	27
46	A Pathogenic Mosaic TP53 Mutation in Two Germ Layers Detected by Next Generation Sequencing. PLoS ONE, 2014, 9, e96531.	2.5	27
47	Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vî³9Vî2+ Î³Î´T cells. OncoImmunology, 2016, 5, e1025194.	4.6	27
48	Persistent Complete Response After Single-agent Sunitinib Treatment in a Case of TFE Translocation Positive Relapsed Metastatic Pediatric Renal Cell Carcinoma. Journal of Pediatric Hematology/Oncology, 2013, 35, e1-e3.	0.6	24
49	Lineage-Independent Tumors in Bilateral Neuroblastoma. New England Journal of Medicine, 2020, 383, 1860-1865.	27.0	23
50	PAX5 Expression in Nonhematopoietic Tissues. American Journal of Clinical Pathology, 2010, 133, 407-415.	0.7	22
51	Bone Marrow-Derived IFN-Producing Killer Dendritic Cells Account for the Tumoricidal Activity of Unpulsed Dendritic Cells. Journal of Immunology, 2008, 181, 6654-6663.	0.8	21
52	Ultrasoundâ€guided core needle biopsy for the diagnosis of rhabdomyosarcoma in childhood. Pediatric Blood and Cancer, 2009, 53, 356-360.	1.5	19
53	Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function. PLoS ONE, 2019, 14, e0216373.	2.5	19
54	Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment. Blood, 2021, 137, 2992-2997.	1.4	19

#	Article	IF	Citations
55	Development of Cellular Immune Responses against PAX5, a Novel Target for Cancer Immunotherapy. Cancer Research, 2008, 68, 8058-8065.	0.9	17
56	Adoptive T-Cell Therapy for Cancer in the United Kingdom: A Review of Activity for the British Society of Gene and Cell Therapy Annual Meeting 2015. Human Gene Therapy, 2015, 26, 276-285.	2.7	17
57	A novel small-molecule inhibitor of IL-6 signalling. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7029-7032.	2.2	16
58	The immune environment of paediatric solid malignancies: evidence from an immunohistochemical study of clinical cases. Fetal and Pediatric Pathology, 2013, 32, 298-307.	0.7	16
59	A Simple and Robust Single-Step Method for CAR-VÎ´1 Î³ÎT Cell Expansion and Transduction for Cancer Immunotherapy. Frontiers in Immunology, 2022, 13, .	4.8	16
60	MYCNderegulation as a potential target for novel therapies in rhabdomyosarcoma. Expert Review of Anticancer Therapy, 2006, 6, 217-224.	2.4	15
61	Noninvasive MRI Native T1 Mapping Detects Response to MYCN-targeted Therapies in the Th-MYCN Model of Neuroblastoma. Cancer Research, 2020, 80, 3424-3435.	0.9	15
62	Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications. Critical Reviews in Oncology/Hematology, 2021, 161, 103325.	4.4	15
63	Migratory and Antigen Presentation Functions of IFN-Producing Killer Dendritic Cells. Cancer Research, 2009, 69, 6598-6606.	0.9	14
64	Licensing of Î³ÎT cells for professional antigen presentation. OncoImmunology, 2012, 1, 1652-1654.	4.6	14
65	Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy. OncoImmunology, 2015, 4, e973808.	4.6	14
66	MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment. Cancer Research, 2019, 79, 2978-2991.	0.9	13
67	Uneventful administration of vincristine in Charcotâ€“Marieâ€“Tooth disease type 1X. Pediatric Blood and Cancer, 2008, 50, 874-876.	1.5	12
68	PAX5 Expression in Rhabdomyosarcoma. American Journal of Surgical Pathology, 2009, 33, 1575-1577.	3.7	12
69	Engineered human mesenchymal stem cells for neuroblastoma therapeutics. Oncology Reports, 2019, 42, 35-42.	2.6	12
70	Novel Treatments and Technologies Applied to the Cure of Neuroblastoma. Children, 2021, 8, 482.	1.5	12
71	Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours. European Journal of Cancer, 2022, 162, 209-220.	2.8	12
72	B-MYB is hypophosphorylated and resistant to degradation in neuroblastoma: Implications for cell survival. Blood Cells, Molecules, and Diseases, 2007, 39, 263-271.	1.4	11

#	Article	IF	Citations
73	Development of anti-PAX3 immune responses; a target for cancer immunotherapy. Cancer Immunology, Immunotherapy, 2007, 56, 1381-1395.	4.2	11
74	Alcohol-abuse drug disulfiram targets pediatric glioma via MLL degradation. Cell Death and Disease, 2021, 12, 785.	6.3	11
75	STAT3 Regulates Proliferation and Immunogenicity of the Ewing Family of TumorsIn Vitro. Sarcoma, 2012, 2012, 1-6.	1.3	10
76	Establishment and phenotyping of neurosphere cultures from primary neuroblastoma samples. F1000Research, 2019, 8, 823.	1.6	10
77	Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR. Pediatric Blood and Cancer, 2006, 46, 820-824.	1.5	9
78	Distant Metastatic Spread of Molecularly Proven Infantile Fibrosarcoma of the Chest in a 2-month-old Girl. Journal of Pediatric Hematology/Oncology, 2014, 36, 231-233.	0.6	9
79	Congenital malignant rhabdoid tumor of the scalp. Journal of Cranio-Maxillo-Facial Surgery, 2012, 40, e258-e260.	1.7	8
80	Characterisation and Validation of Insertions and Deletions in 173 Patient Exomes. PLoS ONE, 2012, 7, e51292.	2.5	8
81	Inflammation: What role in pediatric cancer?. Pediatric Blood and Cancer, 2012, 58, 659-664.	1.5	8
82	Catechins and antitumor immunity. OncoImmunology, 2013, 2, e24443.	4.6	8
83	A Promyelocytic Leukemia Proteinâ€“Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma. Clinical Cancer Research, 2016, 22, 3398-3409.	7.0	8
84	IMMUNOHISTOCHEMICAL NUCLEAR POSITIVITY FOR WT1 IN CHILDHOOD ACUTE MYELOID LEUKEMIA. Fetal and Pediatric Pathology, 2007, 26, 193-197.	0.7	7
85	Combined Effects of Myeloid Cells in the Neuroblastoma Tumor Microenvironment. Cancers, 2021, 13, 1743.	3.7	7
86	Brain lipidâ€“binding protein: a marker of differentiation in neuroblastic tumors. Journal of Pediatric Surgery, 2011, 46, 1197-1200.	1.6	6
87	Licensing of killer dendritic cells in mouse and humans: Functional similarities between IKDC and human blood Î³Î´ T-lymphocytes. Journal of Immunotoxicology, 2012, 9, 259-266.	1.7	6
88	Unleashing the immune response against childhood solid cancers. Pediatric Blood and Cancer, 2017, 64, e26548.	1.5	6
89	The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma. Human Pathology, 2019, 86, 182-192.	2.0	6
90	Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction. Cancers, 2020, 12, 2326.	3.7	6

#	Article	IF	Citations
91	Developing immunotherapies for childhood cancer. Archives of Disease in Childhood: Education and Practice Edition, 2017, 102, 162-165.	0.5	5
92	Long-term kidney function in children with Wilms tumour and constitutional WT1 pathogenic variant. Pediatric Nephrology, 2022, 37, 821-832.	1.7	5
93	The RAC specific guanine nucleotide exchange factor Asef functions downstream from TEL-AML1 to promote leukaemic transformation. Leukemia Research, 2010, 34, 109-115.	0.8	4
94	Regeneration of stalled immune responses to transformed and infected cells using Î³Î´ T cells. Drug Discovery Today, 2014, 19, 787-793.	6.4	4
95	Malignant rhabdoid tumors: A familial condition?. Pediatric Blood and Cancer, 2011, 56, 1-2.	1.5	3
96	Cytogenetic abnormalities in 42 rhabdomyosarcoma: A United Kingdom cancer cytogenetics group study. Medical and Pediatric Oncology, 2001, 36, 259-267.	1.0	3
97	Augmenting human gamma delta lymphocytes for cancer therapy with chimeric antigen receptors. Exploration of Immunology, 0, , 168-179.	0.3	3
98	Importance of Magnetic Resonance Imaging With Diffusion-weighted Imaging in Guiding Biopsy of Nodular Ganglioneuroblastoma: A Case Report. Journal of Pediatric Hematology/Oncology, 2021, 43, e130-e135.	0.6	2
99	Flow cytometry of bone marrow aspirates from neuroblastoma patients is a highly sensitive technique for quantification of low-level neuroblastoma. F1000Research, 0, 10, 947.	1.6	2
100	PAX3-FKHR Chimeric Oncoprotein: Hiding Itself from Immune Detection?. Cell Cycle, 2006, 5, 563-564.	2.6	1
101	The Brn-3b transcription factor regulates the growth, behavior, and invasiveness of human neuroblastoma cells in vitro and in vivo.. Journal of Biological Chemistry, 2015, 290, 888.	3.4	1
102	Antibody based therapy for childhood solid cancers. Current Opinion in Chemical Engineering, 2018, 19, 153-162.	7.8	1
103	Tumor-Associated Antigen Presentation by Î³Î´ T-Cells in Cancer Immunotherapy. Blood, 2014, 124, 1411-1411.	1.4	1
104	Flow cytometry of bone marrow aspirates from neuroblastoma patients is a highly sensitive technique for quantification of low-level neuroblastoma. F1000Research, 2021, 10, 947.	1.6	0
105	Abstract LB-328: SHP-1, p53 and Y674/Y675-phosphorylated-trkA: a molecular pathway and prognostic marker for neuroblastoma. , 2014, , .		0
106	Abstract B128: Chimeric antigen receptor transduced gamma delta T lymphocytes provide enhanced tumor specificity. , 2016, , .		0
107	Adoptive T Cell Therapies for Childrenâ€™s Cancers. , 2018, , 161-174.		0
108	ATRT-20. Novel prognostic molecular signatures for improved risk-classification of Atypical Teratoid Rhabdoid Tumours. Neuro-Oncology, 2022, 24, i7-i7.	1.2	0